Business Wire

MN-ALPEGA

13.10.2020 16:17:08 CEST | Business Wire | Press release

Share
Alpega Partners with FourKites to Deliver Supply Chain Visibility in North America, Europe and Latin America

Alpega, a global provider of cloud-based transportation management systems (TMS), today announced it has partnered with FourKites, a global leader in real-time and predictive supply chain visibility for shippers, carriers and logistics service providers, as part of its strategic value-adding partner ecosystem.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201013005635/en/

The partnership delivers integrated real-time, in-transit freight tracking across all modes and serves Alpega customers of all industries and verticals, enabling improved visibility and reduced supply chain costs.

“Successful end-to-end supply chain planning and execution requires real-time visibility and dependable predictive ETAs,” said Matt Elenjickal, CEO at FourKites. “Our predictive visibility platform leverages machine learning and advanced analytics to provide supply chain professionals with the real-time data needed to make informed, trusted decisions, and to remain agile in the face of any circumstance.”

The partnership combines the modular, scalable transportation management solution, Alpega TMS, with FourKites’ global, multimodal real-time transportation visibility platform. With the largest integrated carrier-base, this integration gives Alpega customers enhanced live shipment tracking and visibility data directly linked to the transportation order in Alpega TMS, providing actionable insights to drive operational efficiencies across supply chain operations.

“Our strategy when it comes to partnerships, is to work with the best to complement our TMS product portfolio,” said Todd DeLaughter, CEO at Alpega Group. “Our partnership with FourKites will provide our customers globally with the critical transportation technology and valuable timely data they need to create a competitive advantage. We look forward to the opportunities this strategic relationship will provide our joint customer base.”

Alpega TMS brings transparency and efficiency to all trading partners across the supply chain through one shared data set and collaborative platform for managing all transportation workflows. Moreover, through its partnership with FourKites, Alpega TMS provides enhanced supply chain visibility across all transportation modes within logistics networks.

Customers can benefit from the Alpega TMS collaborative platform for managing the end-to-end transportation process – from sourcing through settlement – across simple to complex logistics networks; while FourKites provides the end-to-end, real-time predictive visibility and analytics for improved customer service and delivery exception management.

Having pioneered the application of predictive visibility to various aspects of supply chain operations, FourKites’ network now includes more than 400 of the world’s top shippers and their broker and carrier partners - including 18 of the top-20 food and beverage companies and nine of the top-10 CPG companies. The platform tracks over 1 million loads and $100 billion in freight at any given time. FourKites leverages data science breakthroughs and machine learning to provide real-time tracking of shipments across all modes of transportation in 80+ countries, and calculates the industry’s most accurate ETAs. In 2020, FourKites expanded visibility into the yard, creating a new category of software that gives enterprises the ability to proactively manage all their facilities based on real-time in-transit and in-yard freight data and analytics.

“We are happy to have FourKites as a global partner,” said Mark Mc Arthur, Managing Director of Alpega North America. “Their leadership in the real-time visibility platform and digital yard management space will add tangible value to our customer’s businesses. We look forward to working with them.”

About FourKites
FourKites is the largest predictive supply chain visibility platform, delivering real-time visibility and predictive analytics for the broadest network of Global 1000 companies and third-party logistics firms. With the largest repository of supply chain data on the planet, FourKites’ network spans millions of GPS/ELD devices. Using a proprietary algorithm to calculate shipment arrival times, FourKites enables customers to lower operating costs, improve on-time performance and strengthen end-customer relationships. The platform is optimized for mobile devices and equipped with market-leading end-to-end security. For more information, visit http://www.fourkites.com .

About Alpega
Alpega is a global provider of cloud-based transportation management systems (TMS). Alpega enables shippers, their customers, logistics service providers and carriers the ability to collaboratively manage end-2-end transportation activities for increased visibility, capacity and reduced freight spend. By streamlining transportation sourcing, planning, execution, settlement and analytics, Alpega solutions transform local and global supply chains into collaborative ecosystems - bringing transparency and efficiency to all trading partners involved. Alpega’s 200,000+ user community are present in 80 countries worldwide. For more information, visit na.alpegagroup.com for North America; and alpegagroup.com for Europe.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye